Key clinical point: Improved reimbursement for tumor biomarker tests can spur innovation.
Major finding: Tumor biomarker tests are currently undervalued.
Study details: Authors suggest a three-tiered, value-based system that will help drive the development of better tumor biomarker tests.
Disclosures: Research was supported by a grant from AHRQ and from Fashion Footwear Charitable Foundation of New York/QVC Presents Shoes on Sale. All authors reported financial ties to one or more pharmaceutical companies.
Michaela Dinan et al. JCO Precis Oncol. 2019 Sep 18. doi: 10.1200/PO.19.00210.